> ## Content Index
> Fetch the complete content index at: https://bioweek.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# The FDA Just Set a Lung Cancer Survival Bar That No Approved Drug Has Cleared
- URL: https://bioweek.com/the-fda-just-set-a-lung-cancer-survival-bar-that-no-approved-drug-has-cleared/
- Published: 2026-11-16T06:03:49.000Z
- Updated: 2026-11-16T06:03:49.000Z
- Description: The FDA rejected ivonescimab after its global trial missed the statistical bar on overall survival, a benefit no approved regimen in this lung cancer setting has shown, though the drug's China trial did.
- Author: BioWeek
- Tags: Pipeline

The FDA has [rejected](https://www.smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx?ref=bioweek.com) ivonescimab for lung cancer, and the reason it gave is a survival bar that no approved regimen in this setting has cleared. On Sunday, November 15, Summit Therapeutics disclosed that the agency issued a Complete Response Letter for its Biologics License Application covering ivonescimab plus platinum-containing chemotherapy in EGFR-mutated non-small cell lung cancer that progressed after a third-generation EGFR inhibitor. Summit said the FDA determined that substantial evidence of effectiveness was not established without a statistically significant overall survival improvement, and that a progression-free survival benefit alone does not support a positive benefit-risk profile.

The decision is the first US regulatory verdict on a PD-1 x VEGF bispecific antibody, a class analysts have described as the next major backbone of cancer treatment. It lands on the narrowest slice of that class: one indication, in patients whose tumors have already escaped a targeted therapy.

### The standard the FDA applied

The letter's language is procedural. Its implication is not. Summit noted in the same release that there are currently no FDA-approved regimens that have demonstrated a statistically significant overall survival benefit in this patient setting. That is the company's characterization, and it is the crux. Ivonescimab pushed back progression by a wide margin. What it did not do, at the trial's pre-specified analysis, was clear the statistical bar on survival.

That view is not the agency's alone. At the 2025 World Conference on Lung Cancer, Suresh Ramalingam of the Winship Cancer Institute at Emory University, serving as discussant, said that regardless of strategy the progression-free survival gains were relatively modest, and that no regimen had [surpassed](https://www.ilcn.org/ivonescimab-chemotherapy-combo-shows-promise-as-post-tki-option-in-egfr-mutant-nsclc/?ref=bioweek.com) chemotherapy in extending overall survival in this setting. He also noted that checkpoint inhibitors had not worked once EGFR resistance set in.

### What HARMONi actually showed

HARMONi randomized 438 patients 1:1 to ivonescimab plus platinum-doublet chemotherapy or placebo plus chemotherapy. It had two primary endpoints, progression-free survival and overall survival. Enrollment began in China, which supplied 68% of the cohort, before expanding into Europe and North America.

The progression endpoint was met decisively: a hazard ratio of [0.52](https://smmttx.com/news/press-releases/news-details/2026/Updated-HARMONi-Data-Presented-at-WCLC-2026-Demonstrate-Consistent-Overall-Survival-Results-with-Ivonescimab-Plus-Chemotherapy-in-Western-and-Asian-Patients/default.aspx?ref=bioweek.com) (95% CI 0.41-0.66; p<0.0001), median progression-free survival of 6.8 months against 4.4, and an overall response rate of 44.7% against 34.2%. Summit called it the first global Phase III study of an immunotherapy-based regimen to show a statistically significant progression-free survival gain here.

Overall survival did not follow. At the primary analysis, with an April 2025 data cut-off, the hazard ratio was 0.79 (95% CI 0.62-1.01; p=0.057), with median survival of 16.8 months against 14.0\. Later cuts tightened the estimate: 0.78 (nominal p=0.0332) in September 2025 and 0.76 (nominal p=0.0151) by June 2026 in the global intention-to-treat population. The word nominal carries the weight. Those p-values were not adjusted for multiplicity control, so they do not turn a missed primary endpoint into a met one.

### The follow-up problem underneath the data

At the primary survival analysis, median follow-up for Western patients was 9.2 months, shorter than the trial's own median overall survival of 14.0 to 16.8 months. By the June 2026 cut-off, Western follow-up had reached 23.2 months and Asian follow-up 32.7 months, and the hazard ratio held in the same range as the data matured. The FDA's decision rests on the pre-specified analysis rather than on the post-hoc re-readings.

### The China contrast

The sharpest tension sits in Akeso's own trial. In the China-only Phase III HARMONi-A, the final overall survival analysis produced a hazard ratio of [0.74](https://smmttx.com/news/press-releases/news-details/2025/Ivonescimab-Plus-Chemotherapy-Demonstrates-a-Statistically-Significant-Benefit-in-Overall-Survival-with-a-Hazard-Ratio-of-0-74-in-2L-Treatment-of-Patients-with-EGFRm-NSCLC-in-HARMONi-A-Study-Conducted-by-Akeso-in-China/default.aspx?ref=bioweek.com) (95% CI 0.58-0.95, p=0.019), with median survival of 16.8 months against 14.1 at 32.5 months of follow-up. That was the first statistically significant survival benefit for any ivonescimab regimen, and it supported the drug's May 2024 approval in China for this exact indication. The US application rested on the global HARMONi trial.

### Safety was not the issue

The letter did not turn on tolerability. In HARMONi, 16 patients (7.3%) discontinued ivonescimab for treatment-related adverse events against 11 (5.0%) on placebo, and four (1.8%) against five (2.3%) died of treatment-related events. Grade 3 or higher treatment-related events ran 50% against 42.2%.

### What the decision leaves standing

Summit offered no next steps for the EGFR indication. The rest of the program continues: HARMONi-3 in first-line metastatic disease with separate squamous and non-squamous cohorts, HARMONi-7 as monotherapy in high PD-L1 first-line patients, HARMONi-GI3 in colorectal cancer, HARMONi-GU1 with enfortumab vedotin in urothelial carcinoma, and SMT112-216 in renal cell carcinoma, alongside combination work with AstraZeneca, Daiichi Sankyo, Revolution Medicines, GSK and Arcus Biosciences.

The class is not pausing. Pfizer's 3SBio-partnered tivunatamig, BioNTech and Bristol Myers Squibb's pumitamig, Merck's MK-2010 and AbbVie's ABBV-1480 are all moving into global Phase III. AstraZeneca completed a $2 billion equity [investment](https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-completes-equity-investment-in-summit-therapeutics.html?ref=bioweek.com) in Summit in October. Leerink Partners had put the odds of approval at [40%](https://www.fiercebiotech.com/pharma/fda-rejects-summit-therapeutics-pd-1-vegf-ivonescimab-nsclc?ref=bioweek.com) in a November 5 note.

Summit shares fell about [20%](https://squawknews.com/news/931341-summit-therapeutics-shares-fall-20-after-fda-rejection?ref=bioweek.com) overnight into Monday. Akeso fell as much as [31.8%](https://www.scmp.com/business/china-business/article/3374543/akeso-shares-plummet-chinese-firms-cancer-drug-ivonescimab-faces-fda-setback?ref=bioweek.com) in Hong Kong. The verdict that matters is narrower and harder: in post-TKI EGFR-mutated lung cancer, the FDA has now written down a survival standard that the most closely watched drug in the class could not reach.